https://orcid.org/0000-0003-0649-1915
Key Points
This study illustrates the survival benefits of abatacept combined with CNI/MTX in patients with hematologic malignancies undergoing HCT.
The addition of abatacept may provide an approach for alternative donor pool expansion when HLA-identical sibling donors are unavailable.
Abstract
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). Using Center for International Blood and Marrow Transplant Research data, we investigated its impact in patients receiving 7/8 HLA-mismatched unrelated donor (MMUD) or 8/8 HLA-matched unrelated donor (MUD) URD-HCT between 2011 and 2018. Primary outcomes included day-180, 1-year, and 2-year overall survival (OS) and relapse-free survival (RFS) for abatacept + CNI/MTX vs CNI/MTX, CNI/MTX + antithymocyte globulin (ATG), and posttransplant cyclophosphamide-based prophylaxis (PT-Cy). For 7/8 MMUDs, day-180 OS (primary end point supporting FDA approval) was significantly higher for abatacept + CNI/MTX vs CNI/MTX (98% vs 75%; P = .0028). Two-year RFS was significantly higher for abatacept + CNI/MTX vs CNI/MTX (74% vs 49%; P = .0098) and CNI/MTX + ATG (77% vs 35%; P = .0002), and similar vs PT-Cy (72% vs 56%; P = .1058). For 8/8 MUDs, 2-year RFS for abatacept + CNI/MTX was numerically higher vs CNI/MTX (63% vs 52%; P = .1497), with an improved hazard ratio (HR) of 0.46 (0.25-0.86), and vs CNI/MTX + ATG (66% vs 55%; P = .1193; HR, 0.39 [0.21-0.73]), and was similar vs PT-Cy (68% vs 57%; P = .2356; HR, 0.54 [0.26-1.11]). For 7/8 MMUD and 8/8 MUD recipients, abatacept + CNI/MTX prophylaxis improved survival outcomes vs CNI/MTX and CNI/MTX + ATG; outcomes were similar to PT-Cy–based regimens. Abatacept + CNI/MTX may facilitate unrelated donor pool expansion for HCT.
References
1.
Barker
JN
, Boughan
K
, Dahi
PB
, et al. Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis
. Blood Adv
. 2019
;3
(7
):939
-944
.2.
Gragert
L
, Eapen
M
, Williams
E
, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
. N Engl J Med
. 2014
;371
(4
):339
-348
.3.
Lee
SJ
, Klein
J
, Haagenson
M
, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
. Blood
. 2007
;110
(13
):4576
-4583
.4.
Shaw
PJ
, Kan
F
, Woo Ahn
K
, et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
. Blood
. 2010
;116
(19
):4007
-4015
.5.
Saliba
RM
, Alousi
AM
, Pidala
J
, et al. Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis
. Transplant Cell Ther
. 2022
;28
(10
):681
-693
.6.
Zeiser
R
, Blazar
BR
. Acute graft-versus-host disease - biologic process, prevention, and therapy
. N Engl J Med
. 2017
;377
(22
):2167
-2179
.7.
Woolfrey
A
, Klein
JP
, Haagenson
M
, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation
. Biol Blood Marrow Transplant
. 2011
;17
(6
):885
-892
.8.
Gooptu
M
, Antin
JH
. GVHD prophylaxis 2020
. Front Immunol
. 2021
;12
:605726
.9.
Martinez-Cibrian
N
, Zeiser
R
, Perez-Simon
JA
. Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions
. Blood Rev
. 2021
;48
:100792
.10.
Rezvani
AR
, Storb
RF
. Prevention of graft-vs.-host disease
. Expert Opin Pharmacother
. 2012
;13
(12
):1737
-1750
.11.
Battipaglia
G
, Labopin
M
, Kroger
N
, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
. Blood
. 2019
;134
(11
):892
-899
.12.
Mehta
RS
, Saliba
RM
, Chen
J
, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation
. Br J Haematol
. 2016
;173
(3
):444
-455
.13.
Wang
Y
, Wu
DP
, Liu
QF
, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
. J Hematol Oncol
. 2019
;12
(1
):88
.14.
Bolanos-Meade
J
, Hamadani
M
, Wu
J
, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
. N Engl J Med
. 2023
;388
(25
):2338
-2348
.15.
Liu
PC
, Ssu
CT
, Tsao
YP
, et al. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells
. Arthritis Res Ther
. 2020
;22
(1
):64
.16.
Tardella
M
, Di Carlo
M
, Carotti
M
, Giovagnoni
A
, Salaffi
F
. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
. Clin Rheumatol
. 2021
;40
(12
):4861
-4867
.17.
Ruperto
N
, Brunner
HI
, Tzaribachev
N
, et al. Absence of association between abatacept exposure and initial infection in patients with juvenile idiopathic arthritis
. J Rheumatol
. 2021
;48
(7
):1073
-1081
.18.
US Food and Drug Administration
. FDA Approves First Drug to Prevent Graft Versus Host Disease. 2021
Accessed 21 December 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-prevent-graft-versus-host-disease.19.
ORENCIA® (abatacept)
. Package insert. Bristol Myers Squibb; 2024
. Accessed 17 April 2023. http://packageinserts.bms.com/pi/pi_orencia.pdf.20.
Watkins
B
, Qayed
M
, McCracken
C
, et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD
. J Clin Oncol
. 2021
;39
(17
):1865
-1877
.21.
Center For International Blood And Marrow Transplant Research (CIBMTR)
. Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
. Accessed 7 September 2022. https://www.cibmtr.org/DataManagement/ProtocolConsent/ObservationalData/Documents/2022%2006%2027%20Research%20Database%20Protocol%20v9.1.pdf.22.
Kean
LS
, Burns
LJ
, Kou
TD
, et al. Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research Database
. Blood
. 2021
;138
(suppl 1
):3912
.23.
Kean
LS
, Burns
LJ
, Kou
TD
, et al. Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research Database
. Transplant Cell Ther
. 2022
;3
(suppl
):S313
-S314
.24.
Kean
LS
, Burns
LJ
, Kou
TD
, et al. A real-world evidence comparison of 1-year overall survival and relapse-free survival between patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate versus antithymocyte globulin or post-transplant cyclophosphamide following allogeneic hematopoietic cell transplantation
. Blood
. 2022
;140
(suppl 1
):1373
-1375
.25.
Kean
LS
, Burns
LJ
, Kou
TD
, et al. Survival outcomes at 1-year post-allogeneic HCT between patients treated with abatacept in combination with CNI+MTX versus ATG or PT-Cy: a real-world evidence comparison
. Bone Marrow Transpl
. 2023
;58
(suppl 1
):OS05
-07
.26.
Blazar
BR
, Taylor
PA
, Linsley
PS
, Vallera
DA
. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
. Blood
. 1994
;83
(12
):3815
-3825
.27.
Koura
DT
, Horan
JT
, Langston
AA
, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial
. Biol Blood Marrow Transplant
. 2013
;19
(11
):1638
-1649
.28.
Miller
WP
, Srinivasan
S
, Panoskaltsis-Mortari
A
, et al. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression
. Blood
. 2010
;116
(24
):5403
-5418
.29.
Watkins
BK
, Tkachev
V
, Furlan
SN
, et al. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
. J Clin Invest
. 2018
;128
(9
):3991
-4007
.30.
Yu
C
, Linsley
P
, Seidel
K
, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model
. Transplantation
. 2000
;69
(3
):450
-454
.31.
Khandelwal
P
, Yeh
RF
, Yu
L
, et al. Graft-versus-host disease prophylaxis with abatacept reduces severe acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant for beta-thalassemia major with busulfan, fludarabine, and thiotepa
. Transplantation
. 2021
;105
(4
):891
-896
.32.
Ngwube
A
, Shah
N
, Godder
K
, Jacobsohn
D
, Hulbert
ML
, Shenoy
S
. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease
. Blood Adv
. 2020
;4
(16
):3894
-3899
.33.
Raffa
EH
, Srinivasan
A
, Wall
DA
, et al. Abatacept-based graft-versus-host disease prophylaxis in haplo-identical hematopoietic cell transplant in a high-risk cohort
. J Pediatr Hematol Oncol
. 2022
;44
(7
):383
-387
.34.
Holtan
SG
, Hamadani
M
, Wu
J
, et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN
. Blood
. 2022
;140
(suppl 2
). LBA-4.35.
Kean
L
, Siegel
SJ
, Schmalz
JT
, et al. Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study
. Blood
. 2023
;142
(suppl 1
):475
.36.
Shaw
BE
, Jimenez-Jimenez
AM
, Burns
LJ
, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial
. Transplant Cell Ther
. 2023
;29
(3
):208.e1
-208.e6
.37.
Qayed
M
, Watkins
B
, Gillespie
S
, et al. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation
. Blood Adv
. 2022
;6
(3
):746
-749
.38.
Finke
J
, Bethge
WA
, Schmoor
C
, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
. Lancet Oncol
. 2009
;10
(9
):855
-864
.39.
Raghunandan
S
, Gorfinkel
L
, Graiser
M
, et al. Abatacept for the prevention of GvHD in pediatric and adult patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
. Blood
. 2022
;140
(suppl 1
):7653
-7655
.40.
Stenger
EO
, Watkins
B
, Rogowski
K
, et al. Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
. Blood Adv
. 2023
;7
(10
):2196
-2205
.41.
Center for International Blood and Marrow Transplant Research (CIBMTR). Our Centers
. Accessed 6 August 2024. https://www.cibmtr.org/About/WhoWeAre/Centers/Pages/index.aspx.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal